122
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Cardiac failure detection in 30 minutes: new approach based on gold nanoparticles

, , , &
Pages 132-139 | Received 26 Oct 2016, Accepted 15 Feb 2017, Published online: 07 Mar 2017
 

Abstract

Cardiac failure occurs when heart is unable to pump sufficiently to maintain blood flow to meet the body’s needs. The aim of this work is to detect highly expressed genes: follistatin-related protein 1 (FSTL1) in heart failure within 30 minutes, using gold nanoparticles. Gold nanoparticles were prepared by citrate reduction of HAuCl4 3H2O; probe sequence was designed based on the FSTL1 gene region. Preparation of gold nanoprobes (AuNPs) proceeded by treating all the containers with DEPC-treated water, followed by reduction and conjugation. Transmission electron microscopy shows that AuNPs were 10–15 nm in size. The concentration of the nanoprobes was 2.1 nM, and they bind to target. Real-time PCR shows an over-expression of FSTL1 and FSTL3 in heart failure (p < .05). Our data showed that elevated expression of the FSTL1 and FSTL3 is a marker of heart failure as detected within 30 minutes by the synthesised AuNPs; the method is accurate and fast.

Acknowledgements

The authors would like to thank Lorestan University of Medical Sciences.

Disclosure statement

None of the authors has any financial interests to disclose.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.